

ABSTRACT

The use of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-  
5 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable  
derivative thereof, for treating LUTS associated with: OAB (with or without concomitant  
detrusor over activity); pelvic floor dysfunction; or chronic prostatitis, is described.